Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). Headquartered in Watertown, Massachusetts, the company utilizes its proprietary GEODe technology platform to create biologic medicines that overcome traditional challenges in GPCR-targeted drug discovery. Its lead product candidate, TX45, is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, currently in Phase 2 clinical trials for the treatment of Group 2 pulmonary hypertension in heart failure patients with preserved ejection fraction (PH-HFpEF). The company's pipeline also includes TX2100, a GPCR antagonist in development for hereditary hemorrhagic telangiectasia (HHT), and a bi-functional GPCR modulator targeting fibrosis. Tectonic Therapeutic became a publicly traded entity following a reverse merger with AVROBIO, Inc. in June 2024.
